Risk Factors, Microbiologic Profile, and Drug Susceptibility in Adults with Bacterial Community-Acquired Pneumonia in Northeast Nigeria
Based on Nigerian data, gram-negative bacteria—particularly Klebsiella pneumoniae—predominate in bacterial CAP in this region, representing a significant shift from the typical Streptococcus pneumoniae dominance seen in Western populations, with optimal empiric coverage requiring levofloxacin or ceftazidime based on local susceptibility patterns 1, 2.
Microbiologic Profile
The bacterial etiology in northeast Nigeria differs substantially from Western guidelines:
Predominant Pathogens
- Klebsiella pneumoniae: Most frequently isolated (28.1-32.8% of cases) 1, 2
- Streptococcus pneumoniae: Second most common (47.6% in some series) 2
- Staphylococcus aureus: 12.7% of isolates 2
- Streptococcus pyogenes: 6.9% 2
This gram-negative predominance (particularly K. pneumoniae) represents a critical departure from international guidelines that prioritize S. pneumoniae coverage 3. The high frequency of gram-negative organisms in Nigerian CAP likely reflects environmental factors, healthcare access patterns, and population-specific risk factors not captured in Western studies.
Pathogen Identification Rates
Microbiological confirmation was achieved in 81.5% of cases when sputum culture was performed 2, substantially higher than typical Western rates. However, in practice, sputum culture was only requested in 30.6% of admitted patients 4, representing a major diagnostic gap.
Drug Susceptibility Patterns
The antimicrobial resistance profile in northeast Nigeria mandates departure from standard international empiric regimens:
Highest Susceptibility
- Levofloxacin: 77% susceptibility 2
- Ceftazidime: 75.5% 2
- Imipenem: High susceptibility 1
- Ceftriaxone: Effective against predominant isolates 1
- Ofloxacin: 55.8% 2
Poor Susceptibility (Avoid for Empiric Therapy)
- Co-amoxiclav: Only 47.6% susceptibility 2
- Ciprofloxacin: 45.9% 2
- Ceftriaxone: 47.6% in one series 2
- Trimethoprim-sulfamethoxazole: 100% non-susceptibility in pneumococcal isolates 5
Critical caveat: The commonly prescribed empiric regimen of ceftriaxone plus metronidazole 4 shows suboptimal susceptibility (47.6%) and was associated with higher mortality and longer hospital stays 2. This represents a dangerous practice pattern that must be corrected.
For pneumococcal isolates specifically, resistance to macrolides (erythromycin) was present in 20% of cases, though 80% remained susceptible 5. All pneumococcal isolates demonstrated complete resistance to trimethoprim-sulfamethoxazole 5.
Risk Factors and Clinical Characteristics
Demographic Risk Factors
- Age ≥65 years: Independent predictor of mortality (OR 5.947; 95% CI 3.581-17.643) 6
- Mean age: 49-53 years at presentation 1, 4
- Male predominance: 55-64% of cases 6, 7
Comorbidities (Present in 53.8% of patients)
- Systemic hypertension: Most common (24.5%) 1
- HIV infection: Strong independent predictor of mortality (OR 9.444; 95% CI 4.304-20.725) 7; (OR 2.081; 95% CI 1.651-3.237) 6
- COPD: Independent predictor of mortality (OR 10.111; 95% CI 2.370-43.139) 7
- Tobacco smoking: Mortality predictor (OR 3.632; 95% CI 1.459-9.039) 7
- Diabetes mellitus: Common comorbidity 1
Clinical Presentation
- Shortness of breath: 96.1% 1
- Cough: 94.1% 1
- Fever and sputum production: Common 7
- Median time to admission: 3 days from symptom onset 1
Severity and Mortality Predictors
- CURB-65 score ≥2: Independent predictor of mortality 1
- CURB-65 score ≥3: Strong mortality predictor (OR 2.317; 95% CI 1.734-4.719) 6
- Hypoxia: Strongest mortality predictor (OR 11.118; 95% CI 2.607-47.405) 7
- Presence of complications: Independent mortality predictor 1
- Overall mortality: 7.8-17.6% 1, 6
Recommended Empiric Antibiotic Approach for Northeast Nigeria
Given the local microbiologic profile and resistance patterns, empiric therapy should prioritize gram-negative coverage while maintaining pneumococcal activity:
For Hospitalized Non-ICU Patients
Primary recommendation: Levofloxacin 750 mg IV daily OR Ceftazidime 2g IV q8h plus azithromycin 500 mg daily
This deviates from IDSA/ATS guidelines 3 which recommend β-lactam plus macrolide or respiratory fluoroquinolone, because local data demonstrate poor susceptibility to standard β-lactams like ceftriaxone when used alone.
For Severe CAP (ICU Patients)
Primary recommendation: Ceftazidime 2g IV q8h (or imipenem 500 mg IV q6h) PLUS levofloxacin 750 mg IV daily
This provides dual gram-negative coverage while maintaining activity against S. pneumoniae and atypical pathogens, consistent with severe CAP guidelines 8, 9 but adapted for local resistance.
Critical Practice Gaps to Address
- Sputum culture utilization: Only 30.6% of patients had cultures ordered 4—this must increase to ≥80% for hospitalized patients per guidelines 3, 10
- Severity scoring: CURB-65 was documented in only 20% of cases 4—universal severity assessment is mandatory 9
- HIV screening: Performed in only 35% 4—should be universal given strong mortality association 6, 7
- Blood glucose testing: Only 31.3% tested 4—diabetes is a key comorbidity requiring assessment
Diagnostic Approach
All hospitalized CAP patients should receive 3, 10:
- Chest radiograph (performed in most cases)
- Blood cultures before antibiotics
- Sputum Gram stain and culture (if productive cough, good quality specimen)
- Complete blood count, urea, electrolytes, liver function
- Pulse oximetry or arterial blood gas
- HIV testing (given 9.4-fold mortality increase) 7
- Blood glucose (diabetes common comorbidity)
For severe CAP (ICU admission), add 3:
- Urinary antigen tests for Legionella and S. pneumoniae (if available)
- Endotracheal aspirate if intubated
The high pathogen identification rate (81.5%) when cultures are performed 2 justifies aggressive microbiological investigation in this population, allowing targeted de-escalation after 48-72 hours.